Qin Ning Selected Research

Massive Hepatic Necrosis

1/2022	Fibrinogen-like protein 2 deficiency inhibits virus-induced fulminant hepatitis through abrogating inflammatory macrophage activation.
1/2019	Kctd9 Deficiency Impairs Natural Killer Cell Development and Effector Function.
1/2018	Clara Cell 10 kDa Protein Alleviates Murine Hepatitis Virus Strain 3-Induced Fulminant Hepatitis by Inhibiting Fibrinogen-Like Protein 2 Expression.
1/2018	Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice.
1/2017	IL-33 protects murine viral fulminant hepatitis by targeting coagulation hallmark protein FGL2/fibroleukin expression.
10/2015	Correction: The NLRP3 Inflammasome and IL-1β Accelerate Immunologically Mediated Pathology in Experimental Viral Fulminant Hepatitis.
9/2015	The NLRP3 Inflammasome and IL-1β Accelerate Immunologically Mediated Pathology in Experimental Viral Fulminant Hepatitis.
1/2013	Combined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice.
8/2012	Contribution of IL-17 to mouse hepatitis virus strain 3-induced acute liver failure.
11/2011	[KCTD9, a novel potassium channel related gene, was highly expressed in hepatic NK cells and T cells of fulminant hepatitis mice induced by MHV-3].

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qin Ning Research Topics

Disease

41	Chronic Hepatitis B 10/2022 - 07/2003
34	Infections 01/2022 - 03/2003
21	Hepatitis B 01/2022 - 03/2003
19	Fibrosis (Cirrhosis) 06/2022 - 07/2004
16	Massive Hepatic Necrosis 01/2022 - 05/2003
16	Hepatitis 01/2022 - 07/2003
15	Inflammation (Inflammations) 01/2021 - 08/2010
12	Hepatocellular Carcinoma (Hepatoma) 08/2021 - 09/2011
12	Necrosis 10/2019 - 05/2003
11	Acute-On-Chronic Liver Failure 12/2021 - 10/2012
9	Virus Diseases (Viral Diseases) 09/2021 - 03/2003
9	Neoplasms (Cancer) 01/2021 - 10/2008
8	Acute Liver Failure (Fulminant Hepatic Failure) 01/2021 - 05/2003
8	Chronic Obstructive Pulmonary Disease (COPD) 01/2018 - 05/2010
8	Hyperoxia 10/2009 - 02/2004
6	Insulin Resistance 10/2022 - 06/2011
6	Disease Progression 12/2021 - 11/2005
5	Sepsis (Septicemia) 07/2022 - 10/2014
5	COVID-19 01/2022 - 01/2020
5	Liver Diseases (Liver Disease) 06/2021 - 05/2003
5	Liver Failure 01/2021 - 10/2007
5	Bronchopulmonary Dysplasia 10/2009 - 02/2004
4	Non-alcoholic Fatty Liver Disease 06/2022 - 09/2018
4	Chronic Hepatitis C 09/2021 - 10/2016
3	Polyps 01/2021 - 02/2016
3	Obesity 01/2021 - 11/2016
3	Schistosomiasis (Bilharziasis) 10/2020 - 04/2014
3	Alcoholic Fatty Liver 09/2019 - 01/2018
3	Autoimmune Hepatitis 01/2018 - 12/2006
3	Asthma (Bronchial Asthma) 01/2018 - 10/2017
3	Chronic Hepatitis (Chronic Active Hepatitis) 11/2016 - 07/2004
3	Wounds and Injuries (Trauma) 01/2016 - 07/2003
3	Gestational Diabetes (Gestational Diabetes Mellitus) 01/2016 - 02/2014
3	Liver Cirrhosis (Hepatic Cirrhosis) 02/2015 - 01/2014
3	Thrombosis (Thrombus) 07/2008 - 07/2003
2	Shock 07/2022 - 10/2017
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 06/2022 - 06/2011
2	Bacterial Infections (Bacterial Infection) 02/2022 - 09/2021

Drug/Important Bio-Agent (IBA)

38	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2003
21	CytokinesIBA 01/2022 - 10/2007
19	Hepatitis B e AntigensIBA 01/2022 - 12/2013
19	Antiviral Agents (Antivirals)IBA 01/2022 - 09/2011
17	Fibrinogen (Factor I)FDA Link 01/2022 - 05/2003
17	Messenger RNA (mRNA)IBA 09/2019 - 03/2003
16	InterferonsIBA 12/2021 - 10/2014
11	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 01/2016
10	Alanine Transaminase (SGPT)IBA 06/2022 - 02/2012
10	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 10/2007
10	Thromboplastin (Tissue Factor)IBA 05/2015 - 05/2003
9	Interleukin-6 (Interleukin 6)IBA 01/2022 - 08/2012
8	entecavir FDA Link 10/2022 - 10/2012
7	FibrinIBA 01/2018 - 07/2003
6	AntigensIBA 01/2022 - 08/2010
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 06/2022 - 01/2014
5	BilirubinIBA 02/2022 - 04/2016
5	nasIBA 01/2022 - 11/2017
5	Interleukin-17 (Interleukin 17)IBA 01/2022 - 08/2010
5	LipopolysaccharidesIBA 01/2021 - 07/2003
5	Potassium Channels (Potassium Channel)IBA 01/2019 - 11/2008
5	CoagulantsIBA 01/2018 - 05/2003
4	Interferon-alpha (Interferon Alfa)IBA 01/2022 - 01/2021
4	InterleukinsIBA 01/2022 - 06/2014
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 06/2014
4	SofosbuvirIBA 09/2021 - 01/2019
4	Interleukin-10 (Interleukin 10)IBA 10/2020 - 10/2019
4	Telbivudine FDA Link 01/2020 - 01/2014
4	Pharmaceutical PreparationsIBA 01/2019 - 09/2009
4	Transcription Factors (Transcription Factor)IBA 12/2017 - 07/2008
4	Small Interfering RNA (siRNA)IBA 01/2014 - 05/2006
4	Oxygen (Dioxygen)IBA 01/2007 - 02/2004
3	Interleukin-22 (IL-22)IBA 01/2022 - 08/2012
3	LipidsIBA 01/2022 - 01/2019
3	Ferritins (Ferritin)IBA 01/2021 - 01/2020
3	p38 Mitogen-Activated Protein KinasesIBA 01/2021 - 05/2010
3	Urea (Carbamide)FDA LinkGeneric 01/2021 - 10/2017
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2014
3	NitrogenIBA 01/2021 - 04/2003
3	NucleosidesIBA 01/2020 - 01/2014
3	Interleukin-8 (Interleukin 8)IBA 01/2020 - 07/2014
3	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2013
3	InflammasomesIBA 01/2020 - 09/2015
3	AcidsIBA 09/2019 - 04/2003
3	Interleukin-2 (IL2)IBA 09/2019 - 10/2008
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 09/2019 - 03/2013
3	Insulin (Novolin)FDA Link 04/2018 - 03/2013
3	SmokeIBA 01/2018 - 12/2013
3	LigandsIBA 01/2017 - 01/2010
3	Neuroprotective AgentsIBA 02/2016 - 05/2015
3	Glucose (Dextrose)FDA LinkGeneric 08/2015 - 09/2009
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2007 - 01/2007
2	maleic acid (maleate)IBA 10/2022 - 12/2013
2	CreatinineIBA 07/2022 - 10/2017
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 02/2022 - 01/2020
2	AntibodiesIBA 01/2022 - 05/2021
2	Transaminases (Aminotransferases)IBA 01/2022 - 01/2021
2	C-Reactive ProteinIBA 09/2021 - 01/2020
2	Tenofovir (Viread)FDA Link 06/2021 - 05/2019

Therapy/Procedure

23	Therapeutics 08/2021 - 01/2012
4	Liver Transplantation 12/2021 - 10/2014
2	Plasma Exchange 01/2021 - 07/2020